HomeCONGRESS

CONGRESS

View Category
Antithrombotic Anticoagulants

ESC 2018 | MARINER: Rivaroxaban as Thromboprophylaxis after Hospitalization

For acute patients hospitalized for a clinical disease (e.g.: heart failure), indicating rivaroxaban for 6.5 weeks after...
solaci -
Learn More
Chronic Ischemic cardiopathy

ESC 2018 | FUTURE: A Thorn in FFR and More Questions than Answers

As observed at the preliminary analysis that motivated the FUTURE trial early termination, the use of fractional...
solaci -
Learn More
Structural heart disease

ESC 2018 | FRANCE-TAVI: Atrial Fibrillation and Anticoagulation Associated to Mortality in TAVR

Some of the many ongoing randomized studies including patients with atrial fibrillation (AF) might finally answer the...
solaci -
Learn More
ESC 2018

ESC 2018

Here you will find the highlights of the ESC 2018, held on August 25-29 in the city...
solaci -
Learn More
DAY 1

SOLACI-SOCIME 2018 | Endovascular Treatment of Mesenteric Artery Disease

Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr....
solaci -
Learn More
DAY 1

SOLACI-SOCIME 2018 | Retrograde approach: techniques and results

Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr....
solaci -
Learn More
Coronary disease

SOLACI-SOCIME 2018 | New Indications

Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr....
solaci -
Learn More
DAY 1

SOLACI-SOCIME 2018 | When Not to Use a Device: Characteristics of Atrial Septal Defects that Do Not Lead to Percutaneous Closure

Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. In this case see...
solaci -
Learn More